Niina Veitonmäki

Title: Niina Veitonmäki: Innovator in Bispecific Polypeptides

Introduction

Niina Veitonmäki is a prominent inventor based in Lund, Sweden. She has made significant contributions to the field of biotechnology, particularly in the development of bispecific polypeptides. Her work focuses on innovative solutions for targeting cancer cells, showcasing her commitment to advancing medical science.

Latest Patents

Niina holds a patent for bispecific polypeptides against CD137. This invention provides bispecific polypeptides that include a first binding domain, designated B1, which specifically binds to CD137, and a second binding domain, designated B2, which binds specifically to a tumor cell-associated antigen. The patent also covers pharmaceutical compositions of these bispecific polypeptides and their applications in medicine.

Career Highlights

Niina is currently associated with Alligator Bioscience AB, where she continues to push the boundaries of cancer treatment through her innovative research. Her work has garnered attention in the scientific community, contributing to the development of targeted therapies.

Collaborations

Niina collaborates with esteemed colleagues, including Eva Dahlén and Peter Ellmark, who share her vision of advancing cancer treatment through innovative biotechnological solutions.

Conclusion

Niina Veitonmäki's contributions to the field of biotechnology, particularly through her patent on bispecific polypeptides, highlight her role as a leading inventor in cancer research. Her work exemplifies the potential of innovative therapies in improving patient outcomes.